Zoë Johnson

Zoë Johnson

Auto-generated profile, based on publicly available information

Zoë Johnson

Novimmune S.A., Plan-les-Ouates, Switzerland

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 February 2003 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
APAmanda E. I. Proudfoot
Amanda E. I. Proudfoot
THTracy M. Handel
Tracy M. Handel
ZJZoë Johnson
Zoë Johnson
ELElaine K. Lau
Elaine K. Lau
PLPatricia LiWang
Patricia LiWang
MKMarie H. Kosco-Vilbois
Marie H. Kosco-Vilbois
During organogenesis, immunosurveillance, and inflammation, chemokines selectively recruit leukocytes by activating seven-transmembrane-spanning receptors. It has been suggested that an important component of this process is the formation of a haptotactic gradient by immobilization of chemokines on cell surface glycosaminoglycans (GAGs). However, this hypothesis has not been experimentally demonstrated in vivo . In the present study we investigated the effect of mutations in the GAG binding sites of three chemokines, monocyte chemoattractant protein-1/CC chemokine ligand (CCL)2, macrophage-inflammatory protein-1β/CCL4, and RANTES/CCL5, on their ability to recruit cells in vivo . These mutant chemokines retain chemotactic activity in vitro , but they are unable to recruit cells when administered intraperitoneally. Additionally, monomeric variants, although fully active in vitro , are devoid of activity in vivo . These data demonstrate that both GAG binding and the ability to form higher-order oligomers are essential for the activity of particular chemokines in vivo , although they are not required for receptor activation in vitro . Thus, quaternary structure of chemokines and their interaction with GAGs may significantly contribute to the localization of leukocytes beyond migration patterns defined by chemokine receptor interactions.

1 June 2005 in Annual Review of Biochemistry
Verified
Journal Article
Closed access
THT.M. Handel
T.M. Handel
ZJZ. Johnson
Z. Johnson
SCS.E. Crown
S.E. Crown
ELE.K. Lau
E.K. Lau
MSM. Sweeney
M. Sweeney
APA.E. Proudfoot
A.E. Proudfoot
▪ Abstract Immune modulators such as cytokines and growth factors exert their biological activity through high-affinity interactions with cell-surface receptors, thereby activating specific signaling pathways. However, many of these molecules also participate in low-affinity interactions with another class of molecules, referred to as proteoglycans. Proteoglycans consist of a protein core to which glycosaminoglycan (GAG) chains are attached. The GAGs are long, linear, sulfated, and highly charged heterogeneous polysaccharides that are expressed throughout the body in different forms, depending on the developmental or pathological state of the organ/organism. They participate in many biological functions, including organogenesis and growth control, cell adhesion, signaling, inflammation, tumorigenesis, and interactions with pathogens. Recently, it was demonstrated that certain chemokines require interactions with GAGs for their in vivo function. The GAG interaction is thought to provide a mechanism for retaining chemokines on cell surfaces, facilitating the formation of chemokine gradients. These gradients serve as directional cues to guide the migration of the appropriate cells in the context of their inflammatory, developmental, and homeostatic functions. In this review, we discuss GAGs and their interaction with proteins, with a special emphasis on the chemokine system.

1 December 2005 in Cytokine & Growth Factor Reviews
Verified
Journal Article
Closed access
ZJZ. Johnson
Z. Johnson
APA.E. Proudfoot
A.E. Proudfoot
THT.M. Handel
T.M. Handel

1 May 2004 in Journal of Biological Chemistry
Verified
Journal Article
Open access
ELElaine K. Lau
Elaine K. Lau
CPChad D. Paavola
Chad D. Paavola
ZJZoë Johnson
Zoë Johnson
JGJean-Philippe Gaudry
Jean-Philippe Gaudry
EGElena Geretti
Elena Geretti
THTracy M. Handel
Tracy M. Handel
In a recent study, we demonstrated that glycosaminoglycan (GAG) binding and oligomerization are essential for the in vivo function of the chemokines MCP-1/CCL2, RANTES/CCL5, and MIP-1beta/CCL4 (1). Binding to the GAG chains of cell surface proteoglycans is thought to facilitate the formation of high localized concentrations of chemokines, which in turn provide directional signals for leukocyte migration. To understand the molecular details of the chemokine-GAG interaction, in the present study we identified the GAG binding epitopes of MCP-1/CCL2 by characterizing a panel of surface alanine mutants in a series of heparin-binding assays. Using sedimentation equilibrium and cross-linking methods, we also observed that addition of heparin octasaccharide induces tetramer formation of MCP-1/CCL2. Although MCP-1/CCL2 forms a dimer in solution, both a dimer and tetramer have been observed by x-ray crystallography, providing a glimpse of the putative heparin-bound state. When the GAG binding residues are mapped onto the surface of the tetramer, the pattern that emerges is a continuous ring of basic residues encircling the tetramer, creating a positively charged surface well suited for binding GAGs. The structure also suggests several possible functional roles for GAG-induced oligomerization beyond retention of chemokines at the site of production.

9 August 2017 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
APAmana Proudfoot
Amana Proudfoot
ZJZoë Johnson
Zoë Johnson
PBPauline Bonvin
Pauline Bonvin
THTracy Handel
Tracy Handel
Chemokines have two types of interactions that function cooperatively to control cell migration. Chemokine receptors on migrating cells integrate signals initiated upon chemokine binding to promote cell movement. Interactions with glycosaminoglycans (GAGs) localize chemokines on and near cell surfaces and the extracellular matrix to provide direction to the cell movement. The matrix of interacting chemokine–receptor partners has been known for some time, precise signaling and trafficking properties of many chemokine–receptor pairs have been characterized, and recent structural information has revealed atomic level detail on chemokine–receptor recognition and activation. However, precise knowledge of the interactions of chemokines with GAGs has lagged far behind such that a single paradigm of GAG presentation on surfaces is generally applied to all chemokines. This review summarizes accumulating evidence which suggests that there is a great deal of diversity and specificity in these interactions, that GAG interactions help fine-tune the function of chemokines, and that GAGs have other roles in chemokine biology beyond localization and surface presentation. This suggests that chemokine–GAG interactions add complexity to the already complex functions of the receptors and ligands.

1 November 2004 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
ZJZoë Johnson
Zoë Johnson
MKMarie H. Kosco-Vilbois
Marie H. Kosco-Vilbois
SHSuzanne Herren
Suzanne Herren
RCRocco Cirillo
Rocco Cirillo
VMValeria Muzio
Valeria Muzio
APAmanda E I Proudfoot
Amanda E I Proudfoot
A hallmark of autoimmunity and other chronic diseases is the overexpression of chemokines resulting in a detrimental local accumulation of proinflammatory immune cells. Chemokines play a pivotal role in cellular recruitment through interactions with both cell surface receptors and glycosaminoglycans (GAGs). Anti-inflammatory strategies aimed at neutralizing the chemokine system have to-date targeted inhibition of the receptor-ligand interaction with receptor antagonists. In this study, we describe a novel strategy to modulate the inflammatory process in vivo through mutation of the essential heparin-binding site of a proinflammatory chemokine, which abrogates the ability of the protein to form higher-order oligomers, but retains receptor activation. Using well-established protocols to induce inflammatory cell recruitment into the peritoneal cavity, bronchoalveolar air spaces, and CNS in mice, this non-GAG binding variant of RANTES/CCL5 designated [44AANA47]-RANTES demonstrated potent inhibitory capacity. Through a combination of techniques in vitro and in vivo, [44AANA47]-RANTES appears to act as a dominant-negative inhibitor for endogenous RANTES, thereby impairing cellular recruitment, not through a mechanism of desensitization. [44AANA47]-RANTES is unable to form higher-order oligomers (necessary for the biological activity of RANTES in vivo) and importantly forms nonfunctional heterodimers with the parent chemokine, RANTES. Therefore, although retaining receptor-binding capacity, altering the GAG-associated interactive site of a proinflammatory chemokine renders it a dominant-negative inhibitor, suggesting a powerful novel approach to generate disease-modifying anti-inflammatory reagents.